Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development

Portada
George C. Prendergast
John Wiley & Sons, 2004 M04 2 - 351 páginas
Molecular Cancer Therapeutics covers state-of-the-art strategies to identify and develop cancer drug target molecules and lead inhibitors for clinical testing. It provides a thorough treatment of drug target discovery, validation, and development. The introductory chapters provide an overview of pathways to discovery and development of molecular cancer therapeutics. Subsequent chapters progress from initial stages of drug target discovery to drug discovery, development, and testing in preclinical and clinical models. Topics include drug lead screening, drug-to-lead development, proof-of-concept studies, medicinal chemistry issues, intellectual property concerns, and clinical development.
This invaluable reference promotes understanding of steps involved in developing drug leads for industrial partnering and development. It provides an overview of the strategies for discovery and validation of drug target molecules, and discusses cell- and molecule-based drug screening strategies, as well as mouse models for cancer. Coverage also includes how to refine drug leads for suitability in clinical testing, the special issues of clinical testing of molecular-targeted drugs, and intellectual property concerns.
 

Comentarios de la gente - Escribir un comentario

No encontramos ningún comentario en los lugares habituales.

Contenido

Chapter
5
Prendergast
7
CHAPTER
12
Cancer Genetics and Drug Target Selection
41
Journey to
55
1
73
Protein Transduction Strategies for Target
91
Assay Development Issues
119
Transgenic Mouse Models of Cancer
187
4
203
Pharmacodynamic Assays in Cancer Drug
227
119
249
Pharmacokinetic and Toxicology Issues in Cancer
254
Pharmacokinetic
256
I
276
Clinical Development Issues
287

73
140
CHAPTER 8
142
75
171
Acknowledgments
182
85
183
6
301
Intellectual Property and Commercialization
307
Index
329
7
338
Derechos de autor

Otras ediciones - Ver todas

Términos y frases comunes

Pasajes populares

Página 249 - Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
Página 249 - Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res.

Acerca del autor (2004)

Dr. George C. Prendergast was a Benjamin Franklin Scholar at the University of Pennsylvania and graduated magna cum laude with distinction in biochemistry in 1983. He received an M.S. in molecular biophysics and biochemistry from Yale University in 1984 and a Ph.D. in molecular biology from Princeton University in 1989. He was an American Cancer Society Postdoctoral Fellow at the Howard Hughes Medical Institute at New York University and then Senior Research Biochemist at Merck and Co. before being appointed in 1993 to the faculty of The Wistar Institute. In 1995, Dr. Prendergast was recognized by an American Cancer Society Junior Faculty Award and he was named a Pew Scholar in the Biomedical Sciences. In 1999, Dr. Prendergast became Senior Director in the Cancer Research Group at DuPont Pharmaceuticals. In 2002, he was appointed a Senior Investigator at the Lankenau Institute for Medical Research, a biomedical institute affiliated with Thomas Jefferson University in Philadelphia. Dr. Prendergast is currently Senior Editor of Cancer Research, the leading journal in the field.

Información bibliográfica